

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTIONS PASSED AT THE 9TH BOARD MEETING FOR FY2024

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 26 November 2024, the Company duly convened its 9th Board meeting for the financial year ending 31 December 2024 (“**FY2024**”) via teleconference. The said meeting was convened in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were discussed and passed by the eight (8) directors:

1. That the proposed election of Ms. Wang Lei (王磊), an Executive Director of the Company, as Chairman of the Board, be approved.

Ms. Wang Lei, a Chinese national born in August 1971, is a Senior Engineer (Professor Level) (正高级工程师) and holds a postgraduate degree and a Doctorate in Engineering. Ms. Wang has been with Company since July 1993 and has successively worked at Darentang Pharmaceutical Factory, the Planning Office of the Chinese Patent Medicine Department of the Company, the Industrial Department of the Company, and Lerentang Pharmaceutical Factory. Between May 2013 and June 2013, she was a member of the Supervisory Committee of the Company, and from June 2013 to March 2018, she successively served as Deputy General Manager and General Manager of the Company. Ms. Wang was appointed as a Director of the Company for the period from May 2015 to May 2018. Since March 2018, she successively served as Executive Deputy General Manager, General Manager, and Deputy Chairman of Jingwanhong Pharmaceutical. From January 2022 to August 2022, Ms. Wang worked as Deputy General Manager of the Marketing Management Center of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) (“**TPH**”). Since August 2022, she has been serving as General Manager of the Company, and since December 2022, she has also been a Director of the Company.

2. That the proposed appointment of Mr. Xing Jianhua (幸建华) as a Director of the Company, for a term of office lasting until the conclusion of the current Board's term, be approved.

Mr. Xing Jianhua, born in August 1971, holds a postgraduate degree, a Bachelor of Engineering, and a Master of Accounting. He is a Senior Accountant (Professor Level) (正高级会计师), a non-practicing Certified Public Accountant, and a graduate of the 8th cohort of the National Accounting Leading Talent Program organised by the Ministry of Finance of the People's Republic of China. Mr. Xing has extensive experience in financial management, investments, and mergers and acquisitions. From February 2006 to February 2018, he successively served as General Manager of the Finance Department of China General Nuclear Power Group (中国广核集团有限公司), and concurrently as Deputy General Manager and Chief Accountant of CGNPC Uranium Resources Co., Ltd. (中广核铀业发展有限公司). From February 2018 to May 2021, he served as General

Manager of the Finance Department of China Xiongan Group Co., Ltd. (中国雄安集团有限公司).
From December 2021 to November 2024, he was a member of the Supervisory Committee of the Company. Since May 2021, Mr. Xing has been serving as Chief Financial Officer of TPH.

The above resolution No. 2 shall be tabled for shareholders' approval at a general meeting of the Company to be convened in due course.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
26 November 2024